The RTS,S vaccine-a chance to regain the upper hand against malaria?

Sinnis, Photini; Fidock, David A

Sinnis, Photini; Fidock, David A.

Affiliation

Sinnis P; Johns Hopkins Malaria Research Institute and Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA. Electronic address: psinnis1@jhu.edu.
Fidock DA; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA; Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: df2260@cumc.columbia.edu.

Cell ; 185(5): 750-754, 2022 03 03.

Article in En | MEDLINE | ID: mdl-35245476

ABSTRACT

ABSTRACT

Malaria is estimated by the World Health Organization (WHO) to have killed 627,000 individuals worldwide in 2020, with nearly 80% of deaths in African children younger than five. The recent WHO approval of the RTS,S/AS01 vaccine, which targets Plasmodium falciparum pre-erythrocytic stages, provides hope that its use combined with other interventions can help reverse the current malaria resurgence.

Subject(s)

Malaria Vaccines; Malaria, Falciparum; Malaria; Child; Humans; Infant; Malaria/prevention & control; Malaria, Falciparum/prevention & control; Plasmodium falciparum

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Malaria, Falciparum / Malaria Vaccines / Malaria Limits: Child / Humans / Infant Language: En Journal: Cell Year: 2022 Type: Article

Fulltext

XML

PubMed Links

Search on Google